Hosted on MSN12m
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
The stock dropped 8.2% in morning trading, enough to make it the S&P 500 index’s worst performer. It was also on track to suffer its biggest one-day decline since it sank 9.1% on March 15, 2021. The U ...
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results ...
TMCnet10m
DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market
Dario's move follows the success of GLP-1 giants Novo Nordisk and Eli Lilly, whose treatments have reshaped the market. However, while the market leaders focus on medications alone, Dario's ...